<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648059</url>
  </required_header>
  <id_info>
    <org_study_id>28/9/17</org_study_id>
    <nct_id>NCT04648059</nct_id>
  </id_info>
  <brief_title>Epigenetics in Lupus Nephritis</brief_title>
  <acronym>Epi_LN</acronym>
  <official_title>Unmethylated CpG-rich DNA Fragments in TLR-mediated Renal Fibrogenesis of Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli Studi di Brescia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Göttingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a translational study for the identification of epigenetic changes detectable in sera&#xD;
      of patients suffering from Systemic Lupus erythematosus. The aim of the study is to analyze&#xD;
      whether circulating DNA fragments are 1) different in patients with or without Lupus&#xD;
      nephritis and 2) present and detectable in the circulation before the development of Lupus&#xD;
      nephritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Methylated CpG-rich DNA fragments</measure>
    <time_frame>12 months</time_frame>
    <description>it will be analyzed whether circulating CpG-rich DNA fragments are present in patients' blood</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Lupus nephritis +ve</arm_group_label>
    <description>This group consists of patients with Lupus nephritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lupus nephritis -ve</arm_group_label>
    <description>This group consist of patients with SLE without Lupus nephritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling will be performed to allow analyses of epigenetic markers</description>
    <arm_group_label>Lupus nephritis +ve</arm_group_label>
    <arm_group_label>Lupus nephritis -ve</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Circulating CpG-rich DNA fragments&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of a sample of patients with systemic lupus nephritis (SLE).&#xD;
        There will be analyses for the presence of epigenetic markers (methylated CpG-rich DNA&#xD;
        fragments) between two groups: 1) patients with SLE with Lupus nephritis (LN) and 2)&#xD;
        patients with SLE without LN. In the first phase of the study, a cross-sectional sample of&#xD;
        patients will be analyzed. In the second phase of the study, patient samples will be&#xD;
        prospectively analyzed for the presence of these markers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of systemic lupus erythematosus according to the current classification&#xD;
             criteria&#xD;
&#xD;
          -  a subgroup requires the presence of Lupus nephritis (no restriction to specific LN&#xD;
             histologic subtypes)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients not able or unwilling to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>PETER KORSTEN, MD</last_name>
    <phone>055139</phone>
    <phone_ext>8904</phone_ext>
    <email>peter.korsten@med.uni-goettingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PETER KORSTEN</last_name>
      <phone>0551398904</phone>
      <email>peter.korsten@med.uni-goettingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Göttingen</investigator_affiliation>
    <investigator_full_name>Peter Korsten</investigator_full_name>
    <investigator_title>Dr. Peter Korsten</investigator_title>
  </responsible_party>
  <keyword>Epigenetics</keyword>
  <keyword>Methylation</keyword>
  <keyword>Toll-like receptors</keyword>
  <keyword>Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

